|Day Low/High||90.57 / 94.61|
|52 Wk Low/High||31.99 / 99.25|
When the indices aren't offering much opportunity money flows into individual speculative names.
A look at three names to consider in the biotech and biopharma space.
The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.